Amneal Pharmaceuticals (AMRX) Return on Capital Employed (2018 - 2026)

Amneal Pharmaceuticals' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 15.12% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 17.0% year-over-year to 15.12%; the TTM figure through Mar 2026 stood at 15.12% (down 17.0% YoY), while the FY2025 annual figure was 14.55%, up 397.0% from the prior year.
• Return on Capital Employed was 15.12% for Q1 2026 at Amneal Pharmaceuticals, up from 14.29% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 16.46% in Q2 2025 to a low of 4.56% in Q2 2022.
• Historically, Return on Capital Employed has averaged 6.95% across 5 years, with a median of 7.48% in 2023.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed tumbled 773 bps in 2022, then soared 1153 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 3.08% in 2022, then soared by 343 bps to 7.48% in 2023, then soared by 42 bps to 10.6% in 2024, then soared by 35 bps to 14.29% in 2025, then rose by 6 bps to 15.12% in 2026.
• The last three Return on Capital Employed figures came in at 15.12% (Q1 2026), 14.29% (Q4 2025), and 13.51% (Q3 2025), per Business Quant data.